Health Economics›Follicular lymphoma›Relapsed or refractory non-randomized or retrospective data

Relapsed or refractory non-randomized or retrospective data

Follicular lymphoma · 22 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
BVR Variant #01	—	R 142 484	28d	—	—	~5	~R 272 040 indirect	—
Ibrutinib monotherapy Variant #01	—	R 81 964	28d	~44.1 mo	—	~2	~R 163 929 PFS proxy · indirect	15
R-DexaBEAM Variant #01 Partial	—	R 56 818	28d	—	—	~2	~R 113 636 indirect	—
R-FND Variant #01	—	R 38 088	30d	—	—	~4	~R 152 353 indirect	—
Fludarabine and Rituximab (FR) Variant #01	—	R 34 157	28d	—	—	~6	~R 204 943 indirect	—
VR-CP Variant #01	—	R 29 556	21d	—	—	~6	~R 177 337 indirect	—
R-CVP Variant #01	—	R 26 502	21d	—	—	~3	~R 79 505 PFS proxy · indirect	1
Vorinostat and Rituximab Variant #01 Partial	—	R 25 905	21d	—	—	~2	~R 51 809 indirect	—
R-INO Variant #01 Partial	—	R 25 905	28d	—	~9.5 mo	~8	~R 207 238 PFS proxy · indirect	1
Bortezomib monotherapy Variant #03	—	R 6 762	21d	~30.3 mo	—	~8	~R 54 096 PFS proxy · indirect	5
PEP-C Variant #01 Partial	—	R 213	—	—	—	~1	~R 213 indirect	—
Axicabtagene ciloleucel monotherapy Variant #01 Partial	—	—	—	—	—	~1	—	1
Temsirolimus monotherapy Variant #02 Partial	—	—	28d	~4.8 mo	~17.2 mo	~9	—	3
Copanlisib monotherapy Variant #01 Partial	—	—	28d	—	—	~2	—	—
Duvelisib monotherapy Variant #01 Partial	—	—	28d	~13.3 mo	—	~2	—	1
Epcoritamab monotherapy Variant #01 Partial	—	—	28d	—	—	~6	—	—
Mosunetuzumab monotherapy Variant #01 Partial	—	—	21d	—	—	~2	—	—
Vorinostat monotherapy Variant #01 Partial	—	—	28d	~3.1 mo	—	~2	—	1
Inotuzumab ozogamicin monotherapy Variant #01 Partial	—	—	28d	—	~7.7 mo	~5	—	1
Tisagenlecleucel monotherapy Variant #01 Partial	—	—	—	—	—	~1	—	—
Tazemetostat monotherapy Variant #01 Partial	—	—	28d	—	—	~2	—	—
Lisocabtagene maraleucel monotherapy Variant #01 Partial	—	—	—	—	—	~1	—	—

22 of 22 regimens shown